Progressive multifocal leukoencephalopathy (PML)
is an opportunistic, demyelinating infection of the brain caused by the neurotropic JC polyomavirus (JCPyV). Within the central nervous system (CNS), PML-type JCPyV variants can cause a lytic infection. Around 80% of cases occur in AIDS and around 10% in patients with haematological disorders. In 2005, PML was first described in three patients with multiple sclerosis (MS) treated with the IgG4 monoclonal antibody natalizumab. 1, 2 Owing to its efficacy, natalizumab is still available for the MS indication, despite 698 (695 MS, 3 Crohn's disease; Biogen, Safety Update 12/2016) confirmed cases of PML. While the risk of PML has initially been estimated to be around 1/1000 patients treated, it has significantly increased during the past decade and can reach up to 1%-2% if certain risk factors are present. 3, 4 The rising risk prompted development of measures to stratify patients based on treatment duration, prior immunosuppressive therapy, and exposure to the virus as assessed by JCPyV serology. 5 In comparison with natalizumab, the risk of PML is substantially lower for most other immune therapeutics. 6, 7 Nonetheless, PML has been noted in the MS indication also for the sphingosine-1-phosphate receptor modulator fingolimod and dimethylfumarate, 7 and cases of PML have been reported in patients with lupus erythematosus or rheumatoid arthritis that have been treated with the anti-CD20 depleting antibody rituximab. 8 As regulatory approval of the CD20 targeted monoclonal antibody, ocrelizumab is expected for MS in 2017, 9 and novel sphingosine-1-phosphate receptor modulator may become available, 10 PML remains a safety concern in drug development for and management of MS. In the absence of a PML-specific therapy, and in light of a risk stratification model that has not yet shown to markedly decrease the actual numbers of cases with PML per patients treated, it is imperative to search for additional risk markers that may allow a more individualized risk prediction. It has been hypothesized that high and cumulating natalizumab blood concentrations, and alpha-4 integrin saturation, may be linked to an elevated risk of the later development of PML. 11 This has led to off-label use of natalizumab with extension of treatment intervals from the registered 4 to 8 weeks with the intention to reduce occurrence of this dreaded complication. 12 In this issue of the journal, van Kempen and colleagues 13 studied natalizumab drug levels in blood of patients with MS, including those who developed PML. Prior to the diagnosis of PML, five PML patients were assessed for natalizumab drug levels in 2 to 8 pre-PML samples. Results were compared with those in 10 age and sex-matched patients who did not develop PML from a local cohort, and who were tested yearly for a minimum of 7 years during therapy. Serum concentrations of natalizumab were measured longitudinally. Patients with PML had drug levels similar to those of the controls (18.9 vs 23.8 µg/mL) before developing this complication. These observations do not support the view that elevated concentrations of natalizumab are a measurable predictive factor for the subsequent development of PML. In addition, the authors did not find rising drug concentrations in their small selection of MS patients not developing PML, and observed rather stable levels over time.
The article by van Kempen and colleagues addresses a clinically relevant question. Are serum natalizumab concentrations elevated in patients with PML as compared to MS patients that do not develop PML? The answer from this small observational study is no. Is this unexpected? The answer is no again. While previous studies were suggestive of a putative link between low body weight and natalizumab serum concentrations or alpha-4 integrin saturation, 11 no study thus far has been able to relate high serum natalizumab concentrations to the risk of PML. This might be explained by the fact that the alpha-4 receptors are saturated already at lower natalizumab serum concentrations. The logical next question would then be: Can we reduce natalizumab drug concentrations in MS patients maintaining clinical efficacy while lowering the risk of PML? This is still an open question and should be further explored. A recent retrospective study suggested no relevant loss of efficacy by extending the dosing intervals, but was underpowered to assess if this associated with a lower risk of developing PML. 12 Prospectively designed and controlled data collection is needed prior to making evidencebased suggestions to treating physicians.
By re-focusing on the mode of action of natalizumab to combat MS, it becomes obvious that the desirable effects of therapy may naturally be linked to its risks. Natalizumab has been designed to hinder the transmigration of immune cells across the blood-brain barrier into the CNS. Immune cells are key players not only in MS pathogenesis but also in the defence against opportunistic infections including JCPyV. Compared with natalizumab, the risk of PML is substantially lower for other immune therapeutics, with one exception. Efalizumab, a monoclonal antibody directed against leukocyte function-associated antigen-1 (LFA-1), another integrin relevant in immune defence, was approved for the treatment of psoriasis but rapidly withdrawn from the market due to the emergence of PML. As such, also not systematically assessed, an effective dose of a medication that targets integrins such as alpha-4 or LFA-1 may be associated with an elevated risk of PML, and lowering the dose may not necessarily lead to risk reduction.
PML is a complex disease, and besides suppression of adaptive immunity, genetic and environmental factors may be of relevance. Bearing this in mind, and with various alternative therapies under development that have their substance-specific risk profile, it is time to systematically assess the possibilities of an individualized therapy in MS. This will be a long journey, starting from identifying individual pharmacokinetic markers and dosing regimens and also taking account of other factors such as patients and imaging characteristics and genetics. In a population of young patients affected by a disease with a highly variable and mostly unpredictable course, the challenge will be to identify markers not only for therapeutic response but also addressing long-term individual risks. Along this journey, consideration of alternative dosing regimens of registered drugs may be inevitable, and should be captured, systematically, in patient registers.
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